United States
Medizinprodukt-Marktintelligenz für United States. Regulatorische Änderungen, Wettbewerber und Beschaffungstrends.
Länder-Tabelle zuletzt: 9. Aug. 2026 (kann veraltet sein). 7-Tage-Zahl ist live neu berechnet. Tabellenwert war 3004.
Signale der letzten 7 Tage
P/N M4605A: For Sale PHILIPS MP5 MP20 MP30 MP40 MP50 MX550 MX450 Rechargeable Lithium Ion battery 10.8V M4605A Monitor Parts - Listing #4399490 - DOTmed
Medical, Dental & Diagnostic Equipment Auction – 450+ Lots Surplus Auctions - DOTmed
FDA-approved epilepsy drug may help reverse osteoarthritis damage - ScienceDaily
WVU Medicine taps CEO for 3 newly acquired hospitals
FDA approves 1st-of-its-kind Parkinson’s drug
FDA flags patient safety risks from 9 unapproved drugs sold through Amazon
CVS opens 1st pharmacy-focused location in Boston area
HCA Florida hospital names COO
UNC Health plans to build 21st hospital, a 152-bed facility
Epic’s Deterioration Index wins FDA clearance after years of use
Should health systems keep legacy hospital names? What 6 rebrands show
A rural CIO's guide to getting more from technology - Healthcare IT News
Anthropic expands cybersecurity verification tools, invites hospitals to apply - Healthcare IT News
Fsyx overnight IOP-lowering goggles covered by Medicare - Healio
Zoology jobs in Article Releases Astellas And Seagen Complete Enrollment In Ev 103 Trial Cohort K Combining Padcev Enfortumab Vedotin Ejfv With Pembrolizumab As First Line Treatment For Advanced Urothelial Cancer | BioSpace - BioSpace
Validation Engineer jobs in Article Releases Astellas And Seagen Complete Enrollment In Ev 103 Trial Cohort K Combining Padcev Enfortumab Vedotin Ejfv With Pembrolizumab As First Line Treatment For Advanced Urothelial Cancer | BioSpace - BioSpace
Network Administration jobs in Article Releases Astellas And Seagen Complete Enrollment In Ev 103 Trial Cohort K Combining Padcev Enfortumab Vedotin Ejfv With Pembrolizumab As First Line Treatment For Advanced Urothelial Cancer | BioSpace - BioSpace
Biotherapeutics jobs in Article Releases Astellas And Seagen Complete Enrollment In Ev 103 Trial Cohort K Combining Padcev Enfortumab Vedotin Ejfv With Pembrolizumab As First Line Treatment For Advanced Urothelial Cancer | BioSpace - BioSpace
Business/Data Analytics jobs in Article Releases Astellas And Seagen Complete Enrollment In Ev 103 Trial Cohort K Combining Padcev Enfortumab Vedotin Ejfv With Pembrolizumab As First Line Treatment For Advanced Urothelial Cancer | BioSpace - BioSpace
Quality Control jobs in Article Releases Astellas And Seagen Complete Enrollment In Ev 103 Trial Cohort K Combining Padcev Enfortumab Vedotin Ejfv With Pembrolizumab As First Line Treatment For Advanced Urothelial Cancer | BioSpace - BioSpace